278 related articles for article (PubMed ID: 18561513)
21. Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin.
Schweizer A; Foley JE; Kothny W; Ahrén B
Vasc Health Risk Manag; 2013; 9():57-64. PubMed ID: 23431062
[TBL] [Abstract][Full Text] [Related]
22. DPP-4 inhibitor treatment: β-cell response but not HbA
Kozlovski P; Bhosekar V; Foley JE
Vasc Health Risk Manag; 2017; 13():123-126. PubMed ID: 28408838
[TBL] [Abstract][Full Text] [Related]
23. Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes.
Davidson JA; Parente EB; Gross JL
Arq Bras Endocrinol Metabol; 2008 Aug; 52(6):1039-49. PubMed ID: 18820816
[TBL] [Abstract][Full Text] [Related]
24. Vildagliptin , a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin.
Forst T; Bramlage P
Expert Opin Pharmacother; 2014 Jun; 15(9):1299-313. PubMed ID: 24837407
[TBL] [Abstract][Full Text] [Related]
25. Dipeptidyl peptidase-4 inhibitors: 3 years of experience.
Derosa G; Maffioli P
Diabetes Technol Ther; 2012 Apr; 14(4):350-64. PubMed ID: 22324384
[TBL] [Abstract][Full Text] [Related]
26. Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea.
Aso Y; Ozeki N; Terasawa T; Naruse R; Hara K; Suetsugu M; Takebayashi K; Shibazaki M; Haruki K; Morita K; Inukai T
Transl Res; 2012 Jan; 159(1):25-31. PubMed ID: 22153807
[TBL] [Abstract][Full Text] [Related]
27. DPP-4 inhibitors: what may be the clinical differentiators?
Gerich J
Diabetes Res Clin Pract; 2010 Nov; 90(2):131-40. PubMed ID: 20708812
[TBL] [Abstract][Full Text] [Related]
28. Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes.
Ahrén B
Expert Opin Emerg Drugs; 2008 Dec; 13(4):593-607. PubMed ID: 19046129
[TBL] [Abstract][Full Text] [Related]
29. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.
Richter B; Bandeira-Echtler E; Bergerhoff K; Lerch CL
Cochrane Database Syst Rev; 2008 Apr; 2008(2):CD006739. PubMed ID: 18425967
[TBL] [Abstract][Full Text] [Related]
30. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
Guarino E; Nigi L; Patti A; Fondelli C; Dotta F
Expert Opin Pharmacother; 2012 Jun; 13(9):1377-84. PubMed ID: 22397507
[TBL] [Abstract][Full Text] [Related]
31. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
[TBL] [Abstract][Full Text] [Related]
32. Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea.
Xiaoyan C; Jing W; Xiaochun H; Yuyu T; Shunyou D; Yingyu F
Curr Med Res Opin; 2016 Jun; 32(6):1131-6. PubMed ID: 26950829
[TBL] [Abstract][Full Text] [Related]
33. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Lo C; Jun M; Badve SV; Pilmore H; White SL; Hawley C; Cass A; Perkovic V; Zoungas S
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009966. PubMed ID: 28238223
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
Charbonnel B; Karasik A; Liu J; Wu M; Meininger G;
Diabetes Care; 2006 Dec; 29(12):2638-43. PubMed ID: 17130197
[TBL] [Abstract][Full Text] [Related]
35. [Incretin-based therapy for treating patients with type 2 diabetes].
Jermendy G
Orv Hetil; 2011 Nov; 152(48):1931-40. PubMed ID: 22071295
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
Rhee EJ; Lee WY; Min KW; Shivane VK; Sosale AR; Jang HC; Chung CH; Nam-Goong IS; Kim JA; Kim SW;
Diabetes Obes Metab; 2013 Jun; 15(6):523-30. PubMed ID: 23320436
[TBL] [Abstract][Full Text] [Related]
37. Differences in glycemic control across world regions: a post-hoc analysis in patients with type 2 diabetes mellitus on dual antidiabetes drug therapy.
Brath H; Paldánius PM; Bader G; Kolaczynski WM; Nilsson PM
Nutr Diabetes; 2016 Jul; 6(7):e217. PubMed ID: 27376699
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes.
Mu J; Petrov A; Eiermann GJ; Woods J; Zhou YP; Li Z; Zycband E; Feng Y; Zhu L; Roy RS; Howard AD; Li C; Thornberry NA; Zhang BB
Eur J Pharmacol; 2009 Nov; 623(1-3):148-54. PubMed ID: 19765579
[TBL] [Abstract][Full Text] [Related]
39. Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes.
Kalra S
J Assoc Physicians India; 2011 Apr; 59():237-45. PubMed ID: 21755761
[TBL] [Abstract][Full Text] [Related]
40. New combination treatments in the management of diabetes: focus on sitagliptin-metformin.
Green J; Feinglos M
Vasc Health Risk Manag; 2008; 4(4):743-51. PubMed ID: 19065992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]